Clinical Trial: Rifaximin Versus Low FODMAP Diet in Irritable Bowel Syndrome
Document Type
Article
Publication Date
1-1-2026
Abstract
Background: Rifaximin and the low FODMAP diet (LFD) are suggested as second-line therapies for irritable bowel syndrome (IBS). Direct comparative data are limited. Aims: To compare the efficacy of rifaximin and LFD in IBS. Methods: In this single-blind, randomised controlled trial, we allocated adults with IBS to rifaximin or LFD. The primary outcome was composite symptom improvement (abdominal pain/discomfort and stool consistency/frequency) at Week 4. Secondary outcomes included individual symptom improvement, ≥ 50 point reduction in IBS Symptom Severity Scale (IBS-SSS), health-related quality of life (HRQOL), Hospital Anxiety and Depression Scale (HADS), small intestinal bacterial overgrowth (SIBO) eradication, adherence and adverse events. Results: We randomised 100 patients equally (median age 50 years; 52% female; 68% IBS-D; 17% SIBO). Based on the composite symptom assessment, response rates were similar between groups (rifaximin 56.0% vs. LFD 48.0%, p = 0.423) at Week 4. However, rifaximin led to significantly earlier individual symptom improvement at Week 2, including global symptoms (90.0% vs. 72.0%, p = 0.022), bloating (84.0% vs. 58.0%, p = 0.004) and abdominal pain (80.0% vs. 58.0%, p = 0.017). HRQOL and anxiety scores improved in both groups. SIBO eradication was observed in 63.6% (rifaximin) and 50.0% (LFD). Adherence was significantly better with rifaximin (95.9% vs. 77.8%, p = 0.008). No serious adverse events occurred. Conclusion: Rifaximin is as effective as LFD in treating IBS over 4 weeks. However, it provides faster symptom relief and higher treatment adherence, making it a practical alternative for symptom management. Trial Registration: ClinicalTrials.gov: NCT number: NCT04841980.
Keywords
bacterial overgrowth, disorder of gut brain interaction, irritable bowel syndrome, low FODMAP diet, rifaximin
Publication Title
Alimentary Pharmacology and Therapeutics
ISSN
02692813
DOI
10.1111/apt.70420
Recommended Citation
Chuah, Kee Huat; Loo, Qing Yuan; Loh, Audrey Joe Chii; Leong, Jing Yi; Chan, Wah Loong; Khoo, Xin Hui; Wong, Kim Leng; Panirsheeluam, Sarala; Natarajan, Vicraman; Ng, Ai Kah; Abdul Majid, Hazreen; and Mahadeva, Sanjiv, "Clinical Trial: Rifaximin Versus Low FODMAP Diet in Irritable Bowel Syndrome" (2026). Research Publications (2026 to 2030). 1862.
https://knova.um.edu.my/research_publications_2026_2030/1862
Volume
63
Issue
2
First Page
210
Last Page
221